Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming "Global Drug Discovery Company"
May 28, 2007
- Further Revision of Prescription Form Discussed at Chuikyo
May 28, 2007
- Korosho Proposes Increasing Generics' Share to 30% by FY2012
May 28, 2007
- JSMI General Assembly
May 28, 2007
- GENERICS NEWS IN BRIEF
May 28, 2007
- Baxter Focuses on BioScience, Med. Delivery, Renal Therapies: Mr Lema
May 28, 2007
- R&D NEWS IN BRIEF
May 28, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 21, 2007
- Nissan Chemical, Taisho License NM-702 to Milford
May 21, 2007
- On-Line Medical Bill Processing Starting
May 21, 2007
- GSK Recommences Supply of Relenza
May 21, 2007
- JSC to Start Antibacterial Chemotherapy Specialist Certification System
May 21, 2007
- Quintiles Receives Increasing Number of Orders on ECG Analysis Services
May 21, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2007
- Korosho Continues Hearings to Increase Price Agreement Rates
May 21, 2007
- SURVEY／Dry Eyes Most Common Health Problem: Healthclick
May 21, 2007
- Tamiflu Jumps to Top Position: Rep Track
May 21, 2007
- Wyeth Works to Eliminate "Drug Lag" with Strong R&D Pipeline
May 21, 2007
- BUSINESS NEWS IN BRIEF
May 21, 2007
- Takeda: Strong Growth in Sales, Profits with 49.3% of Sales Overseas
May 21, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…